Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions
Authors:
- NiharikaNINiharika
- Samir Kumar PatraSPSamir Kumar Patra
- 22 May 2026
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (9) , 317-342
Abstract
No abstract availableKeywords
Funding Information
- Council for Scientific and Industrial Research, South Africa
- University Grants Commission
- Indian Council of Medical Research
This publication has 208 references indexed in Scilit:
- Bladder CancerJAMA, 2020
- BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cellsCancer Medicine, 2019
- Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genesCancer, 2018
- Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008Cancer, 2016
- Association Between Smoking and Risk of Bladder Cancer Among Men and WomenJAMA, 2011
- Structure and Function of Mammalian DNA MethyltransferasesChemBioChem, 2010
- Cancer Incidence Before and After Kidney TransplantationJAMA, 2006
- Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivoInternational Journal of Cancer, 2004
- Methyl‐CpG‐binding domain 2Cancer, 2004
- DNA adducts in urothelial cells: Relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smokeInternational Journal of Cancer, 1996